Pivekimab Sunirine For Injection 2 mg Suppliers & Bulk Manufacturers
Available Forms: Lyophilised powder vial (IV infusion)
Available Strengths: 2 mg
Reference Brands: Decnupaz (AbbVie)
Category: Oncology Cancer Care
Pivekimab sunirine (Decnupaz, AbbVie) is a CD123-directed antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), approved by the US FDA in May 2026. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.
Manufacture or export Pivekimab Sunirine For Injection? List it or send an offer →
Product Description:
Pivekimab sunirine is an antibody-drug conjugate. The antibody binds CD123, the receptor for interleukin-3, which is present at very high levels on the cancer cells of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It carries a DNA-alkylating payload into those cells to kill them.
BPDCN is a rare, aggressive blood cancer that often appears first as skin lesions and then involves the bone marrow. The US FDA approved pivekimab sunirine as Decnupaz in May 2026 for BPDCN. It is given by intravenous infusion from 2 mg powder vials. It was developed by ImmunoGen, now part of AbbVie, and is also being studied in acute myeloid leukaemia.
Sourcing and licensing notes. Pivekimab sunirine is patented and made only by AbbVie; there is no biosimilar. We confirm registration status for each destination before quoting.
How Pivekimab Sunirine For Injection is supplied today, and licensing ahead of patent expiry
Where pivekimab sunirine is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Decnupaz · FDA · May 2026 |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.
Decnupaz, from AbbVie. The US FDA approved it in May 2026.
CD123, a receptor found at very high levels on BPDCN cells.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Zanidatamab For Injection
Strength:
300 mg
Form: Lyophilised powder vial (IV infusion)
Reference Brands: Ziihera (Jazz Pharmaceuticals; originator Zymeworks)
View DetailsSerplulimab Injection
Strength:
100 mg/10 mL
Form: Concentrate vial (IV infusion)
Reference Brands: Hetronifly (EU), Hansizhuang (China) — Shanghai Henlius
View DetailsTelisotuzumab Vedotin For Injection
Strength:
20 mg, 100 mg
Form: Lyophilised powder vial (IV infusion)
Reference Brands: Emrelis (AbbVie)
View DetailsGedatolisib For Injection
Strength:
180 mg
Form: Powder vial (IV infusion)
Reference Brands: Revtorpyk (Celcuity)
View Details
Lapatinib 250 Mg Tablet
Strength:
250 mg
Form: Tablets
Reference Brands: Herduo (India), Tykerb (USA/EU)
View Details
Usually answered within 48 hours | GMP documents shared before you commit
